Natasja Brooijmans

Development and validation of a modular, extensible docking program: DOCK 5

Demetri T. Moustakas, P. Therese Lang, Scott C.‐H. Pegg et al. · Journal of Computer-Aided Molecular Design · 2006 · 438 citations

Life Sciences, Computer Engineering, Operating Systems +8

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

Margit Hagel, Chandra Miduturu, Michael P. Sheets et al. · Cancer Discovery · 2015 · 315 citations · Full text

Medicine, Oncology, Pharmacology +17

A precision therapy against cancers driven by <i>KIT/PDGFRA</i> mutations

Erica Evans, Alexandra K. Gardino, Joseph L. Kim et al. · Science Translational Medicine · 2017 · 214 citations

Medicine, Oncology, Pharmacology +10

Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound <b>26</b> (PKI-587), a Highly Efficacious Dual Inhibitor

Aranapakam M. Venkatesan, Christoph M. Dehnhardt, Efren Delos Santos et al. · Journal of Medicinal Chemistry · 2010 · 212 citations · Full text

Medicine, Oncology, Pharmacology +14

Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies

Jack Bikker, Natasja Brooijmans, Allan Wissner et al. · Journal of Medicinal Chemistry · 2009 · 163 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +14